Cellular immune response to cryptic epitopes during therapeutic gene transfer
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The immune response has been implicated as a critical factor in determining the success or failure of clinical gene therapy trials. Generally, such a response is elicited by the desired transgene product or, in some cases, the delivery system. In the current study, we report the previously uncharacterized finding that a therapeutic cassette currently being used for human investigation displays alternative reading frames (ARFs) that generate unwanted protein products to induce a cytotoxic T lymphocyte (CTL) response. In particular, we tested the hypothesis that antigenic epitopes derived from an ARF in coagulation factor IX (F9) cDNA can induce CTL reactivity, subsequently killing F9-expressing hepatocytes. One peptide (p18) of 3 candidates from an ARF of the F9 transgene induced CD8 + T cell reactivity in mice expressing the human MHC class I molecule B0702. Subsequently, upon systemic administration of adeno-associated virus (AAV) serotype 2 vectors packaged with the F9 transgene (AAV2/F9), a robust CD8 + CTL response was elicited against peptide p18. Of particular importance is that the ARF epitope-specific CTLs eliminated AAV2/F9-transduced hepatocytes but not AAV2/F9 codon-optimized (AAV2/F9-opt)-transduced liver cells in which p18 epitope was deleted. These results demonstrate a previously undiscovered mechanism by which CTL responses can be elicited by cryptic epitopes generated from a therapeutic transgene and have significant implications for all gene therapy modalities. Such unforeseen epitope generation warrants careful analysis of transgene sequences for ARFs to reduce the potential for adverse events arising from immune responses during clinical gene therapy protocols.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several reports have shown immune responses and/or toxicities from genomic contaminants that may result in the expression of unintended epitopes [49][50][51].”
From The AAV2.7m8 capsid packages a higher degree of heterogeneous vector genomes than AAV2 (2024) · cites this paper as [49]
Citations
Cites
Kozak, M. (1986) · Cell · doi:10.1016/0092-8674(86)90762-2 · Cited by 4,741 · cited 1×
“S1); however, an ORF localized to nucleotides 413–604 ( 1 frame shift, named ARF1) of the F9 cDNA contained a Kozak sequence with an A at 3 and a G at 4 with respect to the ATG start codon of the ARF1 (12), which potentially translates a 64-aa peptide (Fig.”
BackgroundManno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381 · cited 1×
“AAV virus production was described previously (21).”
Self-citationAdeno-associated Virus Serotypes: Vector Toolkit for Human Gene Therapy
Wu, Z., Asokan, A., & Samulski, R. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.009 · Cited by 922
Self-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 2×
“Lastly, AAV2 capsids do not elicit a CTL response in B0702 transgenic mice after muscle injection of a high dose of AAV2 vectors (8).”
BackgroundYang, Y., Ertl, H. C. J., & Wilson, J. M. (1994) · Immunity · doi:10.1016/1074-7613(94)90074-4 · Cited by 611
Karttunen, J., Sanderson, S., & Shastri, N. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.13.6020 · Cited by 418
Yang, Y., Jooss, K. U., Su, Q., Ertl, H. C. J., & Wilson, J. M. (1996) · PubMed · Cited by 375
Flotte, T. R., Afione, S. A., Solow, R., Drumm, M. L., Markakis, D., Guggino, W. B., Zeitlin, P. L., & Carter, B. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53762-5 · Cited by 342
Wu, Z., Sun, J., Zhang, T., Yin, C., Yin, F., Van Dyke, T., Samulski, R. J., & Monahan, P. E. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300355 · Cited by 153 · cited 1×
“In other work, we have generated a codon-optimized F9 construct (F9-opt), which induces higher F9 production in mice after AAV delivery compared with the wild-type F9 cDNA (15).”
BackgroundSelf-citationHaberman, R. P., McCown, T. J., & Samulski, R. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.18.8732-8739.2000 · Cited by 139 · cited 1×
“Considering AAV vectors, the inverted terminal repeats have been shown previously to contain non-TATA-like promoter activity, in addition to chimeric liverspecific expression, adding another layer of complexity to transgene expression in this context (18, 19).”
BackgroundSelf-citationWang, L., Figueredo, J., Calcedo, R., Lin, J., & Wilson, J. M. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.001 · Cited by 113
Constitutive Display of Cryptic Translation Products by MHC Class I Molecules
Schwab, S. R., Li, K. C., Kang, C., & Shastri, N. (2003) · Science · doi:10.1126/science.1085650 · Cited by 112
Pre-existing AAV Capsid-specific CD8+ T Cells are Unable to Eliminate AAV-transduced Hepatocytes
Li, H., Murphy, S. L., Giles-Davis, W., Edmonson, S., Xiang, Z., Li, Y., Lasaro, M. O., High, K. A., & Ertl, H. C. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300090 · Cited by 108
Identification of mouse AAV capsid-specific CD8+ T cell epitopes
Sabatino, D. E., Mingozzi, F., Hui, D. J., Chen, H., Colosi, P., Ertl, H. C. J., & High, K. A. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.009 · Cited by 91
Li, C., Hirsch, M., Asokan, A., Zeithaml, B., Ma, H., Kafri, T., & Samulski, R. J. (2007) · Journal of Virology · doi:10.1128/jvi.00529-07 · Cited by 87
Self-citationIdentification of Cryptic MHC I–restricted Epitopes Encoded by HIV-1 Alternative Reading Frames
Cardinaud, S., Moris, A., Février, M., Rohrlich, P.-S., Weiss, L., Langlade-Demoyen, P., Lemonnier, F. A., Schwartz, O., & Habel, A. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031869 · Cited by 85
Serody, J. S., Collins, E. J., Tisch, R., Kuhns, J. J., & Frelinger, J. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.9.4961 · Cited by 79
Self-citationDetermination of Specific CD4 and CD8 T Cell Epitopes after AAV2- and AAV8-hF.IX Gene Therapy
Chen, J., Wu, Q., Yang, P., Hsu, H.-C., & Mountz, J. D. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.10.006 · Cited by 76
Alternative Translational Products and Cryptic T Cell Epitopes: Expecting the Unexpected
Ho, O., & Green, W. R. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.12.8283 · Cited by 52
Schirmbeck, R., Riedl, P., Fissolo, N., Lemonnier, F. A., Bertoletti, A., & Reimann, J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4647 · Cited by 36
Alexander, J., Oseroff, C., Sidney, J., & Sette, A. (2003) · Human Immunology · doi:10.1016/s0198-8859(02)00786-3 · Cited by 24
Self-citation
Cited by
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Self-citationImmune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“82 Animal studies show that it is possible to express epitopes from ARFs.”
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Kaufmann, K. B., Büning, H., Galy, A., Schambach, A., & Grez, M. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202287 · Cited by 276
“An alternative explanation suggested by mouse studies is the induction of a cytotoxic T ‐ cell response against an epitope produced from the factor IX transgene upon, e.g . usage of an alternative reading frame (Li et al, 2009).”
Metadata
- Authors
- Li, C., Goudy, K., Hirsch, M., Asokan, A., Fan, Y., Alexander, J., Sun, J., Monahan, P., Seiber, D., Sidney, J., Sette, A., Tisch, R., Frelinger, J., & Samulski, R. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Departments of bMicrobiology and Immunology,
- Gene Therapy Center, and
- Pharmexa-Epimmune, 5820 Nancy Ridge Drive, Suite 100, San Diego, CA 92121; and
- Pediatrics and Genetics (US)
- La Jolla Institute for Immunology (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2009-06-30
- Volume
- 106
- Issue
- 26
- Pages
- 10770-10774
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2705599
- OpenAlex
- W2020307339
- Cited by
- 79
- References
- 22
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 3 · 2023: 2 · 2021: 4 · 2020: 4 · 2019: 1 · 2018: 5 · 2017: 9 · 2016: 6 · 2015: 5 · 2014: 5 · 2013: 12 · 2012: 2
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- University of Washington
- National Institutes of Health (5p01gm059299-10)
- National Heart, Lung, and Blood Institute (P01HL051818, P01HL066973)
- National Institute of General Medical Sciences (5P01 GM 059299, P01 GM-059299)
- National Institute of Allergy and Infectious Diseases (R01AI052435, R01AI058014)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- cryptic epitopes, alternative reading frame, cytotoxic T lymphocytes, coagulation factor IX, adeno-associated virus vectors, CD8+ T cell responses, codon optimization, immune response to gene therapy
- MeSH terms
- Dependovirus, Amino Acid Sequence, Animals, Epitopes, Chlorocebus aethiops, Cytotoxicity, Immunologic, Factor IX, Genetic Vectors, Humans, Hybridomas, Immunity, Cellular, Mice, Inbred C57BL, Mice, Transgenic, Oligopeptides, Spleen, T-Lymphocytes, Cytotoxic, Transfection, HLA-B Antigens, Genetic Therapy, Open Reading Frames, CD8-Positive T-Lymphocytes, Coculture Techniques, COS Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.